Eli Lilly developed the diabetes drug Mounjaro, which is also marketed as Zepbound for obesity.
Mounjaro is the brand name for tirzepatide, a medicine approved for improving blood-sugar control in adults with type 2 diabetes. The same active ingredient is sold as Zepbound for chronic weight management in eligible adults, under separate regulatory indications.
Eli Lilly and Company was founded in 1876 by Colonel Eli Lilly, a pharmaceutical chemist and Union Army veteran. The Indianapolis-based company has produced medicines in areas including diabetes, oncology, immunology, and neuroscience.
Mounjaro and Zepbound are not interchangeable descriptions of the same approved use: branding and labeling depend on the medical indication. Eli Lilly’s success with tirzepatide contributed to major changes in the company’s revenue outlook and market capitalization.